NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/10/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization829.45 mln
Float186 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.14
Reliable
1-Year Forecast
12.50
Transformational upside
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.01
Debt-free
ROE
-44.05
Deeply negative
Business Description
CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, focused on developing cancer treatments that work more precisely within the tumor environment. Its core technology, the PROBODY platform, is designed to activate cancer-fighting drugs only at the tumor site, reducing harm to healthy tissue and improving patient safety. The company has several drug candidates in development, including treatments that engage the immune system to attack cancer cells, and maintains partnerships with major pharmaceutical companies such as Amgen, Bristol Myers Squibb, and Merck. Founded in 2008, CytomX continues to build a broad pipeline of next-generation cancer therapies across multiple treatment approaches.
